GlassScriptPhysician profile
Kirit A Desai
NPI 1487761961
$2,072.36
in general payments reported to CMS, 2019-2025
20 companies · $78.47 in 2025
The $78.47 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $314 · 2020: $115 · 2021: $515 · 2022: $505 · 2023: $352 · 2024: $193 · 2025: $78.47.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $624.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $623.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $380.77 | 2021-2025 | Jardiance |
| Merck Sharp & Dohme LLC | $255.47 | 2021-2024 | Verquvo |
| Janssen Pharmaceuticals, INC | $251.15 | 2019-2023 | Xarelto |
| Novartis Pharmaceuticals Corporation | $238.75 | 2019-2022 | |
| Amgen INC. | $153.71 | 2020-2022 | |
| Amarin Pharma, INC. | $116.49 | 2019-2021 | |
| Novo Nordisk INC | $114.80 | 2020-2025 | Wegovy |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $87.15 | 2019-2024 | Lifevest |
| Edwards Lifesciences Corporation | $68.20 | 2023 | Edwards Sapien 3 Transcatheter Heart Valve (Thv), Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Astrazeneca Pharmaceuticals LP | $65.66 | 2021-2023 | Farxiga |
| E.R. Squibb & Sons, L.L.C. | $59.30 | 2021-2023 | Eliquis |
| Cook Medical LLC | $57.11 | 2019-2024 | Zilver Ptx |
| Boston Scientific Corporation | $42.81 | 2021 | |
| Kiniksa Pharmaceuticals International, Plc | $42.08 | 2024 | Arcalyst |
| Kowa Pharmaceuticals America, INC. | $33.06 | 2020-2023 | Livalo |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $31.43 | 2022 | |
| Scpharmaceuticals INC. | $25.23 | 2025 | |
| Lilly USA, LLC | $23.31 | 2023 | Mounjaro |
| Tactile Systems Technology INC | $13.57 | 2019 | |
| Preventice Services, LLC | $12.31 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kirit Desai listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.